.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,875,872

« Back to Dashboard

Claims for Patent: 6,875,872

Title: Compounds
Abstract:The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Inventor(s): Lindberg; Per Lennart (Molndal, SE), Von Unge; Sverker (Fjaras, SE)
Assignee: AstraZeneca (Sodertalje, SE)
Application Number:09/690,044
Patent Claims: 1. Magnesium salt of (-)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole in an optical purity of at least about 94% enantiomeric excess.

2. The compound according to claim 1, when the optical purity is at least 94% enantiomeric excess.

3. The compound according to claim 1 or 2, wherein the compound is in crystaline form.

4. Magnesium salt of (-)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H -benzimidazole in an optical purity of at least about 98.4% enantiomeric excess.

5. The compound according to claim 4, wherein the optical purity is at least 98.4% enantiomeric excess.

6. The compound according to claim 4 or 5, wherein the compound is in crystaline form.

7. Magnesium salt of (-)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H -benzimidazole in an optical purity of at last about 99.8% enantiomeric excess.

8. The compound according to claim 7, wherein the optical purity is at least 99.8% enantiomeric excess.

9. The compound according to claim 7 or 8, wherein the compound is in crystalline form.

10. Magnesium salt of (-).sub.5 -methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benz imidazole in an optical purity of at least about 99.9% enantiomeric excess.

11. The compound according to claim 10, wherein the optical purity is at least 99.9% enantiomeric excess.

12. The compound according to claim 10, wherein the compound is in crystalline form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc